Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer PatientsBusiness Wire • 10/20/25
Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential SymposiumBusiness Wire • 10/12/25
Natera Announces Publication of Signatera™ Validation Study in Testicular CancerBusiness Wire • 09/30/25
Signatera™ Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study ShowsBusiness Wire • 09/29/25
Natera, Inc. (NTRA) Presents at Bernstein 2nd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/24/25
Natera, Inc. (NTRA) Presents At Baird Global Healthcare Conference 2025 TranscriptSeeking Alpha • 09/10/25
Signatera™ Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder CancerBusiness Wire • 08/28/25
Natera Shares Rise on the Launch of AI Platform for Precision OncologyZacks Investment Research • 08/25/25
Natera to Present Signatera™ Data at the IASLC World Conference on Lung CancerBusiness Wire • 08/25/25
Natera Technology Featured in 300+ Peer-Reviewed Publications, Underscoring Scientific Leadership in Precision MedicineBusiness Wire • 08/22/25
Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic InnovationBusiness Wire • 08/22/25
IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy BenefitBusiness Wire • 08/18/25
Compared to Estimates, Natera (NTRA) Q2 Earnings: A Look at Key MetricsZacks Investment Research • 08/08/25
Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited ConditionsBusiness Wire • 08/07/25